{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T18:49:37Z","timestamp":1772131777187,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["UID\/BIA\/04050\/2020"],"award-info":[{"award-number":["UID\/BIA\/04050\/2020"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000055"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000055"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["UIDB\/50026\/2020"],"award-info":[{"award-number":["UIDB\/50026\/2020"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PPBI-POCI-01-0145-FEDER-022122"],"award-info":[{"award-number":["PPBI-POCI-01-0145-FEDER-022122"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/146065\/2019"],"award-info":[{"award-number":["SFRH\/BD\/146065\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2020.05779"],"award-info":[{"award-number":["2020.05779"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["COVID\/BD\/153456\/2023"],"award-info":[{"award-number":["COVID\/BD\/153456\/2023"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/145955\/2019"],"award-info":[{"award-number":["SFRH\/BD\/145955\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008814","name":"Universidade do Minho","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008814","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Free Radical Biology and Medicine"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.freeradbiomed.2025.04.017","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T11:49:38Z","timestamp":1744372178000},"page":"192-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["3-Bromopyruvate boosts the effect of chemotherapy in acute myeloid leukemia by a pro-oxidant mechanism"],"prefix":"10.1016","volume":"234","author":[{"given":"Joana","family":"Pereira-Vieira","sequence":"first","affiliation":[]},{"given":"Sara","family":"Granja","sequence":"additional","affiliation":[]},{"given":"S\u00f3nia Pires","family":"Celeiro","sequence":"additional","affiliation":[]},{"given":"Catarina","family":"Barbosa-Matos","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Preto","sequence":"additional","affiliation":[]},{"given":"Od\u00edlia","family":"Queir\u00f3s","sequence":"additional","affiliation":[]},{"given":"Young Hee","family":"Ko","sequence":"additional","affiliation":[]},{"given":"Margarida","family":"Casal","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1770-4544","authenticated-orcid":false,"given":"F\u00e1tima","family":"Baltazar","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.freeradbiomed.2025.04.017_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.freeradbiomed.2025.04.017_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation.V2012.1.1.3797038","article-title":"Treatment of acute myeloid leukemia: are we making progress?","volume":"2012","author":"Burnett","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"10.1016\/j.freeradbiomed.2025.04.017_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.freeradbiomed.2025.04.017_bib4","doi-asserted-by":"crossref","first-page":"8817","DOI":"10.2147\/CMAR.S177894","article-title":"Midostaurin in acute myeloid leukemia: an evidence-based review and patient selection","volume":"11","author":"Abbas","year":"2019","journal-title":"Cancer Manag. Res."},{"issue":"6","key":"10.1016\/j.freeradbiomed.2025.04.017_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000583","article-title":"Targeting IDH1 and IDH2 mutations in acute myeloid leukemia: emerging options and pending questions","volume":"5","author":"Wouters","year":"2021","journal-title":"HemaSphere"},{"key":"10.1016\/j.freeradbiomed.2025.04.017_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.584974","article-title":"Targeting bcl-2 proteins in acute myeloid leukemia","volume":"10","author":"Wei","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.freeradbiomed.2025.04.017_bib7","article-title":"The mechanism of warburg effect-induced chemoresistance in cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"issue":"3191","key":"10.1016\/j.freeradbiomed.2025.04.017_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.freeradbiomed.2025.04.017_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.freeradbiomed.2025.04.017_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1600200","article-title":"Fundamentals of cancer metabolism","volume":"2","author":"DeBerardinis","year":"2016","journal-title":"Sci. Adv."},{"issue":"10","key":"10.1016\/j.freeradbiomed.2025.04.017_bib11","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood-2014-02-554204","article-title":"A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value","volume":"124","author":"Chen","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.freeradbiomed.2025.04.017_bib12","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3892\/ol.2016.4600","article-title":"Resistance to chemotherapy is associated with altered glucose metabolism in acute myeloid leukemia","volume":"12","author":"Song","year":"2016","journal-title":"Oncol. Lett."},{"issue":"11","key":"10.1016\/j.freeradbiomed.2025.04.017_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2017.81","article-title":"High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells","volume":"31","author":"Poulain","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.freeradbiomed.2025.04.017_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1189\/jlb.0710417","article-title":"The level of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome","volume":"89","author":"Herst","year":"2011","journal-title":"J. Leukoc. Biol."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2025.04.017_bib15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.leukres.2007.04.014","article-title":"Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60\u03c10 cells","volume":"32","author":"Herst","year":"2008","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.freeradbiomed.2025.04.017_bib16","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10863-016-9670-z","article-title":"The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside","volume":"48","author":"Azevedo-Silva","year":"2016","journal-title":"J. Bioenerg. Biomembr."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2025.04.017_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0304-3835(01)00667-X","article-title":"Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase","volume":"173","author":"Ko","year":"2001","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.freeradbiomed.2025.04.017_bib18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/pharmaceutics16040442","article-title":"Glucose metabolism as a potential therapeutic target in cytarabine-resistant acute myeloid leukemia","volume":"16","author":"Pereira-Vieira","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.freeradbiomed.2025.04.017_bib19","article-title":"Targeting lactate metabolism by inhibiting MCT1 or MCT4 impairs leukemic cell proliferation, induces two different related death-pathways and increases chemotherapeutic sensitivity of acute myeloid leukemia cells","volume":"10","author":"Saulle","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2025.04.017_bib20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10863-012-9428-1","article-title":"Role of monocarboxylate transporters in human cancers: state of the art","volume":"44","author":"Pinheiro","year":"2012","journal-title":"J. Bioenerg. Biomembr."},{"issue":"47","key":"10.1016\/j.freeradbiomed.2025.04.017_bib21","doi-asserted-by":"crossref","first-page":"82803","DOI":"10.18632\/oncotarget.20294","article-title":"Monocarboxylate transporter 1 (MCT1), a tool to stratify acute myeloid leukemia (AML) patients and a vehicle to kill cancer cells","volume":"8","author":"Lopes-Coelho","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.freeradbiomed.2025.04.017_bib22","first-page":"1511","article-title":"Monocarboxylate transporters as targets and mediators in cancer therapy response","volume":"29","author":"Baltazar","year":"2014","journal-title":"Histol. Histopathol."},{"issue":"3","key":"10.1016\/j.freeradbiomed.2025.04.017_bib23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/cancers11030317","article-title":"Tumor energy metabolism and potential of 3-bromopyruvate as an inhibitor of aerobic glycolysis: implications in tumor treatment","volume":"11","author":"Fan","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.freeradbiomed.2025.04.017_bib24","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3892\/or.2015.4511","article-title":"3-bromopyruvate and sodium citrate target glycolysis, suppress survivin, and induce mitochondrial-mediated apoptosis in gastric cancer cells and inhibit gastric orthotopic transplantation tumor growth","volume":"35","author":"Wang","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.freeradbiomed.2025.04.017_bib25","doi-asserted-by":"crossref","unstructured":"A. Pereira-Nunes et al., \u201cCombination Therapy With CD147\u2010Targeted Nanoparticles Carrying Phenformin Decreases Lung Cancer Growth - Pereira\u2010Nunes - 2023 - Advanced Biology - Wiley Online Library,\u201d Combination Therapy With CD147-Targeted Nanoparticles Carrying Phenformin Decreases Lung Cancer Growth. Accessed: December. 2, 2023. [Online]. Available: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/adbi.202300080.","DOI":"10.1002\/adbi.202300080"},{"issue":"14","key":"10.1016\/j.freeradbiomed.2025.04.017_bib26","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.3390\/cancers13143468","article-title":"MCT1 is a new prognostic biomarker and its therapeutic inhibition boosts response to temozolomide in human glioblastoma","volume":"13","author":"Miranda-Gon\u00e7alves","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.freeradbiomed.2025.04.017_bib27","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1111\/jcmm.13642","article-title":"Bioenergetic modulators hamper cancer cell viability and enhance response to chemotherapy","volume":"22","author":"Tavares-Valente","year":"2018","journal-title":"J. Cell Mol. Med."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2025.04.017_bib28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.canlet.2015.05.015","article-title":"Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells","volume":"365","author":"Amorim","year":"2015","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2025.04.017_bib29","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1124\/jpet.113.206714","article-title":"Regulation of death induction and chemosensitizing action of 3-bromopyruvate in myeloid leukemia cells: energy depletion, oxidative stress, and protein kinase activity modulation","volume":"348","author":"Calvi\u00f1o","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2025.04.017_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41420-024-01800-2","article-title":"Inhibition of NRF2 enhances the acute myeloid leukemia cell death induced by venetoclax via the ferroptosis pathway","volume":"10","author":"Yu","year":"2024","journal-title":"Cell Death Discov."},{"issue":"10","key":"10.1016\/j.freeradbiomed.2025.04.017_bib31","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1111\/jcmm.13737","article-title":"Signalling mechanisms that regulate metabolic profile and autophagy of acute myeloid leukaemia cells","volume":"22","author":"Pereira","year":"2018","journal-title":"J. Cell Mol. Med."},{"issue":"6","key":"10.1016\/j.freeradbiomed.2025.04.017_bib32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/10245332.2017.1402454","article-title":"Repression of oxidative phosphorylation sensitizes leukemia cell lines to cytarabine","volume":"23","author":"Yucel","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/j.freeradbiomed.2025.04.017_bib33","unstructured":"Leibniz Institute DSMZ: Details.\u201d Accessed: Jun. 11, 2024. [Online]. Available: https:\/\/www.dsmz.de\/collection\/catalogue\/details\/culture\/ACC-3."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2025.04.017_bib34","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41467-022-28737-3","article-title":"The Glycolytic Gatekeeper PDK1 defines different metabolic states between genetically distinct subtypes of human acute myeloid leukemia","volume":"13","author":"Erdem","year":"2022","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2025.04.017_bib35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bcmd.2012.10.005","article-title":"A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3","volume":"50","author":"Lichtman","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"issue":"10","key":"10.1016\/j.freeradbiomed.2025.04.017_bib36","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2165\/00003088-200241100-00002","article-title":"Clinical pharmacokinetics of cytarabine formulations","volume":"41","author":"Hamada","year":"2002","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2025.04.017_bib37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF02983222","article-title":"Pharmacokinetics of a standard dose of cytarabine in a patient with acute promyelocytic leukemia undergoing continuous ambulatory peritoneal dialysis","volume":"77","author":"Takeuchi","year":"2003","journal-title":"Int. J. Hematol."},{"issue":"6","key":"10.1016\/j.freeradbiomed.2025.04.017_bib38","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0006-2952(98)00343-8","article-title":"Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts","volume":"57","author":"Houba","year":"1999","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.freeradbiomed.2025.04.017_bib39","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3390\/cancers13050966","article-title":"Response and toxicity to cytarabine therapy in leukemia and lymphoma: from dose puzzle to pharmacogenomic biomarkers","volume":"13","author":"Di Francia","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.freeradbiomed.2025.04.017_bib40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00280-019-03856-9","article-title":"A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias","volume":"84","author":"Lin","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"7","key":"10.1016\/j.freeradbiomed.2025.04.017_bib41","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","article-title":"A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin","volume":"57","author":"Gewirtz","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.freeradbiomed.2025.04.017_bib42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/2162-3619-2-20","article-title":"Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia","volume":"2","author":"Momparler","year":"2013","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2025.04.017_bib43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40364-020-00242-z","article-title":"The significant role of redox system in myeloid leukemia: from pathogenesis to therapeutic applications","volume":"8","author":"Kaweme","year":"2020","journal-title":"Biomark. Res."},{"issue":"9","key":"10.1016\/j.freeradbiomed.2025.04.017_bib44","doi-asserted-by":"crossref","first-page":"658","DOI":"10.18632\/oncotarget.321","article-title":"Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1","volume":"2","author":"Heasman","year":"2011","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.freeradbiomed.2025.04.017_bib45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.acra.2006.09.059","article-title":"Local toxicity of hepatic arterial infusion of hexokinase II inhibitor, 3-bromopyruvate: in vivo investigation in normal rabbit model","volume":"14","author":"Chang","year":"2007","journal-title":"Acad. Radiol."},{"key":"10.1016\/j.freeradbiomed.2025.04.017_bib46","series-title":"Vitamins and Hormones","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/bs.vh.2022.09.002","article-title":"Chapter Five - the antioxidant glutathione","volume":"vol. 121","author":"Averill-Bates","year":"2023"},{"key":"10.1016\/j.freeradbiomed.2025.04.017_bib47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mehy.2017.01.014","article-title":"The promising anticancer drug 3-bromopyruvate is metabolized through glutathione conjugation which affects chemoresistance and clinical practice: an evidence-based view","volume":"100","author":"El Sayed","year":"2017","journal-title":"Med. Hypotheses"},{"issue":"40","key":"10.1016\/j.freeradbiomed.2025.04.017_bib48","doi-asserted-by":"crossref","first-page":"65614","DOI":"10.18632\/oncotarget.11592","article-title":"Glutathione may have implications in the design of 3-bromopyruvate treatment protocols for both fungal and algal infections as well as multiple myeloma","volume":"7","author":"Nied\u017awiecka","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.freeradbiomed.2025.04.017_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6806","article-title":"Oxidative stress is two-sided in the treatment of acute myeloid leukemia","volume":"13","author":"Fan","year":"2024","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2025.04.017_bib50","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12935-024-03393-3","article-title":"The sensitivity of acute myeloid leukemia cells to cytarabine is increased by suppressing the expression of Heme oxygenase-1 and hypoxia-inducible factor 1-alpha","volume":"24","author":"Sadeghi","year":"2024","journal-title":"Cancer Cell Int."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2025.04.017_bib51","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3390\/biom13020353","article-title":"Reactive oxygen species and NRF2 signaling, friends or foes in cancer?","volume":"13","author":"Wang","year":"2023","journal-title":"Biomolecules"},{"issue":"12","key":"10.1016\/j.freeradbiomed.2025.04.017_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122772","article-title":"Nrf2, the master regulator of anti-oxidative responses","volume":"18","author":"Vomund","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.freeradbiomed.2025.04.017_bib53","first-page":"171","article-title":"The effect of N-Acetyl-Cysteine on NRF2 antioxidant gene expression in asthenoteratozoospermia men: a clinical trial study","volume":"14","author":"Jannatifar","year":"2020","journal-title":"Int J Fertil Steril"},{"key":"10.1016\/j.freeradbiomed.2025.04.017_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102497","article-title":"NAC, NAC, Knockin\u2019 on Heaven's door: interpreting the mechanism of action of N-acetylcysteine in tumor and immune cells","volume":"57","author":"Kalyanaraman","year":"2022","journal-title":"Redox Biol."},{"issue":"6","key":"10.1016\/j.freeradbiomed.2025.04.017_bib55","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood-2007-05-092510","article-title":"Internal tandem duplication of FLT3 (FLT3\/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML","volume":"111","author":"Sallmyr","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.freeradbiomed.2025.04.017_bib56","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"23","key":"10.1016\/j.freeradbiomed.2025.04.017_bib57","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.3390\/ijms20236003","article-title":"The role of reactive oxygen species in acute myeloid leukaemia","volume":"20","author":"Sillar","year":"2019","journal-title":"Int. J. Mol. Sci."}],"container-title":["Free Radical Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891584925002278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891584925002278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:53:04Z","timestamp":1762314784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891584925002278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":57,"alternative-id":["S0891584925002278"],"URL":"https:\/\/doi.org\/10.1016\/j.freeradbiomed.2025.04.017","relation":{},"ISSN":["0891-5849"],"issn-type":[{"value":"0891-5849","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"3-Bromopyruvate boosts the effect of chemotherapy in acute myeloid leukemia by a pro-oxidant mechanism","name":"articletitle","label":"Article Title"},{"value":"Free Radical Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.freeradbiomed.2025.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}